Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (12935)
All Articles published online
|
Publishing Process of This Article
|
Dec 13, 2018 (publication date) through Dec 28, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastrointestinal Pharmacology and Therapeutics
ISSN
2150-5349
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Rawla P, Sunkara T, Ofosu A, Gaduputi V. Potassium-competitive acid blockers - are they the next generation of proton pump inhibitors? World J Gastrointest Pharmacol Ther 2018; 9(7): 63-68 [PMID: 30595950 DOI: 10.4292/wjgpt.v9.i7.63] |
|---|---|
| URL: | https://www.wjgnet.com/2150-5349/full/v9/i7/63.htm |
| Number | Citing Articles |
| 1 |
AVIJIT MAZUMDER, NAVEEN KUMAR, SAUMYA DAS. A Comprehensive Review of Gastroesophageal Reflux Disease (GERD) Treatment and its Clinical Perspectives. International Journal of Pharmaceutical Sciences and Nanotechnology(IJPSN) 2023; 16(6): 7093 doi: 10.37285/ijpsn.2023.16.6.9
|
| 2 |
Chinami Yamawaki, Shunsaku Nakagawa, Keiko Ikuta, Yurie Katsube, Natsuki Imayoshi, Yuki Shigetsura, Daiki Hira, Shinya Yamamoto, Takeshi Matsubara, Motoko Yanagita, Tomohiro Terada. Association between Proton Pump Inhibitors, Immune Checkpoint Inhibitors, and Acute Kidney Injury: A Nested Case–Control Study. Kidney360 2024; 5(9): 1262 doi: 10.34067/KID.0000000000000528
|
| 3 |
Xianlian Wang, Yongmei Xu, Zaiwei Zong, Jinna Cai, Chunlin Chen, Qingwei Zhang, Xun Sun, Jianqi Li. Design, synthesis and biological evaluation of novel 5-methyl-2,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole derivatives as potent potassium-competitive acid blockers. Bioorganic & Medicinal Chemistry 2022; 64: 116765 doi: 10.1016/j.bmc.2022.116765
|
| 4 |
Sameh A. Lashen, Mohammed M. Shamseya, Ayman M. Shamseya, Fahmy H. Hablass. Efficacy of Vonoprazan vs. Pantoprazole or Non-acid Suppression in Prevention of Post-variceal Ligation Ulcer Bleeding in Portal Hypertension: A Multi-arm Randomized Controlled Trial. Journal of Clinical and Experimental Hepatology 2023; 13(6): 962 doi: 10.1016/j.jceh.2023.05.008
|
| 5 |
Sufeng Zhou, Lijun Xie, Chen Zhou, Yuqing Zhao, Lu Wang, Sijia Ding, Juan Chen, Bei Zhu, Mei Su, Feng Shao. Keverprazan, a novel potassium-competitive acid blocker: Single ascending dose safety, tolerability, pharmacokinetics, pharmacodynamics and food effect in healthy subjects. European Journal of Pharmaceutical Sciences 2023; 190: 106578 doi: 10.1016/j.ejps.2023.106578
|
| 6 |
Min Seo Lee, Jihoon Lee, Minyoung Pang, John Kim, Hyunju Cha, Banyoon Cheon, Min-Koo Choi, Im-Sook Song, Hye Suk Lee. In Vitro Metabolism and Transport Characteristics of Zastaprazan. Pharmaceutics 2024; 16(6): 799 doi: 10.3390/pharmaceutics16060799
|
| 7 |
Chao Liu, Bing Cheng Feng, Yan Zhang, Li Xiang Li, Xiu Li Zuo, Yan Qing Li. The efficacy of vonoprazan for management of post‐endoscopic submucosal dissection ulcers compared with proton pump inhibitors: A meta‐analysis. Journal of Digestive Diseases 2019; 20(10): 503 doi: 10.1111/1751-2980.12813
|
| 8 |
Wen-xin Wang, Rui-jie Li, Xiong-fei Li. Efficacy and Safety of Potassium-Competitive Acid Blockers vs Proton Pump Inhibitors for Peptic Ulcer Disease or Postprocedural Artificial Ulcers: A Systematic Review and Meta-analysis. Clinical and Translational Gastroenterology 2024; 15(9): e1 doi: 10.14309/ctg.0000000000000754
|
| 9 |
Inyoung Hwang, Sang Chun Ji, Jaeseong Oh, Hyojin Kim, Hyunju Cha, John Kim, Chang‐Seok Lee, Kyung‐Sang Yu, SeungHwan Lee. Randomised clinical trial: Safety, tolerability, pharmacodynamics and pharmacokinetics of zastaprazan (JP‐1366), a novel potassium‐competitive acid blocker, in healthy subjects. Alimentary Pharmacology & Therapeutics 2023; 57(7): 763 doi: 10.1111/apt.17406
|
| 10 |
Yuchul Jeong, Beom Lee, Se-Hyeon Han. RETRACTED: A Phase III Head-to-Head Study to Compare the Efficacy and Safety of Fexuprazan and Esomeprazole in Treating Patients with Erosive Esophagitis. Journal of Clinical Medicine 2024; 13(11): 3262 doi: 10.3390/jcm13113262
|
| 11 |
JaHyun Ho, Bokyoung Kim, Kue Sook Kim, Chang-Ho Jihn, Min-Young Kim, Dae Ryong Kang, You Hyun Park, Jihyun Ahn. Statin Supply and Polydrug Use in Older Adults: A Focus on Drug Combinations that Reduce Bone Density. Annals of Geriatric Medicine and Research 2021; 25(4): 269 doi: 10.4235/agmr.21.0103
|
| 12 |
Daniel Martin Simadibrata, Ari Fahrial Syam, Yeong Yeh Lee. A comparison of efficacy and safety of potassium‐competitive acid blocker and proton pump inhibitor in gastric acid‐related diseases: A systematic review and meta‐analysis. Journal of Gastroenterology and Hepatology 2022; 37(12): 2217 doi: 10.1111/jgh.16017
|
| 13 |
György Miklós Buzás. Dual acid-pump blocking as novel therapeutic approach to treatment of acid-related diseases. Medical Hypotheses 2024; 187: 111338 doi: 10.1016/j.mehy.2024.111338
|
| 14 |
Vishal Padwale, Vijendra Kirnake, Ravi Daswani, Akshay Kodmalwar, Anusha Gupta. A Comprehensive Review on the Efficacy and Safety of Vonoprazan in the Management of Gastric Acid-Related Diseases. Cureus 2024; doi: 10.7759/cureus.64777
|
| 15 |
Muhammad Miftahussurur, Boby Pratama Putra, Yoshio Yamaoka. The Potential Benefits of Vonoprazan as Helicobacter pylori Infection Therapy. Pharmaceuticals 2020; 13(10): 276 doi: 10.3390/ph13100276
|
| 16 |
György Miklós Buzás, Péter Birinyi. Newer, Older, and Alternative Agents for the Eradication of Helicobacter pylori Infection: A Narrative Review. Antibiotics 2023; 12(6): 946 doi: 10.3390/antibiotics12060946
|
| 17 |
Huiyun Zhu, Qian Xue, Yingxiao Song, Zhenyu Zhang, Xing Li, Shengxiang Lyu, Qiang Zhan, Fei Liu, Lungen Lu, Liang Zhong, Weixing Chen, Dong Shao, Yanbing Ding, Deliang Liu, Xiaozhong Yang, Zhiming Huang, Zhaoshen Li, Yiqi Du. Efficacy and safety of tegoprazan (LXI-15028) vs. esomeprazole in patients with erosive esophagitis: A multicenter, randomized, double-blind, non-inferiority phase Ⅲ trial. Chinese Medical Journal 2024; doi: 10.1097/CM9.0000000000003276
|
| 18 |
Yu Kyung Cho, Jae Hak Kim, Hyun‐Soo Kim, Tae‐Oh Kim, Jung‐Hwan Oh, Suck Chei Choi, Jeong Seop Moon, Sang Kil Lee, Sung Woo Jung, Sung Soo Kim, Hye‐Kyung Jung, Sang Pyo Lee, Gab‐Jin Cheon, Moo In Park, Hwoon‐Yong Jung, Kwang Hyun Ko, In Kyung Sung, Si Hyung Lee, Ju Yup Lee, Soo Teik Lee, Poong‐Lyul Rhee, Nayoung Kim, Su Jin Hong, Hyun Jin Kim, Gwang Ha Kim, Kwang Jae Lee, Sung Kook Kim, Woon Geon Shin, Oh Young Lee. Randomised clinical trial: comparison of tegoprazan and lansoprazole as maintenance therapy for healed mild erosive oesophagitis. Alimentary Pharmacology & Therapeutics 2023; 57(1): 72 doi: 10.1111/apt.17255
|
| 19 |
S. Veni Sri Ambika, S. Gunasekaran, D. Velmurugan, Irena Kostova. Chromatographic fractionation and molecular docking of bioactive component from the leaves of Solanum nigrum for binding affinity with proton pump to inhibit gastric acid secretion. Materials Today: Proceedings 2022; 68: 491 doi: 10.1016/j.matpr.2022.07.427
|
| 20 |
Kanishka Uthansingh, Kenguruka Sidoine, Swarup Kumar Patnaik, Girish Kumar Pati, Rabindra Nath Padhy. Natural Products for Antibacterial Drug Development: Recent Advancement of Computational Approach. 2024; : 167 doi: 10.1007/978-981-97-9634-2_8
|
| 21 |
Angela Tietto, Sofia Faggin, Carmelo Scarpignato, Edoardo Vincenzo Savarino, Maria Cecilia Giron. Safety of potassium-competitive acid blockers in the treatment of gastroesophageal reflux disease. Expert Opinion on Drug Metabolism & Toxicology 2024; : 1 doi: 10.1080/17425255.2024.2397433
|
| 22 |
Jeremy Klein, Robert T. Kavitt. Gastroesophageal Reflux Disease. 2023; : 61 doi: 10.1007/978-3-031-48241-0_8
|
| 23 |
Kevin Z. Huang, H. Christian Weber. Potassium-competitive acid blockers and acid-related disorders. Current Opinion in Endocrinology, Diabetes & Obesity 2024; 31(3): 107 doi: 10.1097/MED.0000000000000858
|
| 24 |
Yoo-Seong Jeong, Min-Soo Kim, Nora Lee, Areum Lee, Yoon-Jee Chae, Suk-Jae Chung, Kyeong-Ryoon Lee. Development of Physiologically Based Pharmacokinetic Model for Orally Administered Fexuprazan in Humans. Pharmaceutics 2021; 13(6): 813 doi: 10.3390/pharmaceutics13060813
|
| 25 |
Alla Turshudzhyan, Sonia Samuel, Angela Tawfik, Micheal Tadros. Rebuilding trust in proton pump inhibitor therapy. World Journal of Gastroenterology 2022; 28(24): 2667-2679 doi: 10.3748/wjg.v28.i24.2667
|
| 26 |
Kyungwon Yoon, Jung-Tae Kim, Won-Gun Kwack, Donghyun Kim, Kyung-Tae Lee, Seungwon Yang, Sangmin Lee, Yeo-Jin Choi, Eun-Kyoung Chung. Potentially Inappropriate Medication Use in Patients with Dementia. International Journal of Environmental Research and Public Health 2022; 19(18): 11426 doi: 10.3390/ijerph191811426
|
| 27 |
FNU Tanvir, Gurkamal Singh Nijjar, Smriti Kaur Aulakh, Yasmeen Kaur, Sumerjit Singh, Kanwarmandeep Singh, Abhinandan Singla, Ajay Pal Singh Sandhu, Shivansh Luthra, Harman Antaal. Gastroesophageal Reflux Disease: New Insights and Treatment Approaches. Cureus 2024; doi: 10.7759/cureus.67654
|
| 28 |
Lidi Tian, Dan Xiang, Feili Yue, Runjie Li, Youping Zhou. Efficacy and safety of vonoprazan versus proton pump inhibitors in the treatment of peptic ulcer disease: a systematic review and network meta-analysis for randomized controlled trails. Frontiers in Nutrition 2024; 11 doi: 10.3389/fnut.2024.1436993
|
| 29 |
Sufeng Zhou, Lijun Xie, Chen Zhou, Lu Wang, Juan Chen, Sijia Ding, Bei Zhu, Mei Su, Feng Shao. Keverprazan, a novel potassium‐competitive acid blocker: Multiple oral doses safety, tolerability, pharmacokinetics, and pharmacodynamics in healthy subjects. Clinical and Translational Science 2023; 16(10): 1911 doi: 10.1111/cts.13598
|
| 30 |
Min-Gul Kim, Yong-Jin Im, Jong-Hwan Lee, Eun-Young Kim, Sang Woo Yeom, Jong Seung Kim. Comparison of hepatotoxicity of tegoprazan, a novel potassium-competitive acid blocker, with proton pump inhibitors using real-world data: A nationwide cohort study. Frontiers in Medicine 2023; 9 doi: 10.3389/fmed.2022.1076356
|
| 31 |
Jung Sunwoo, Sang Chun Ji, Jaeseong Oh, Mu Seong Ban, Ji Yeon Nam, Bongtae Kim, Geun Seog Song, Kyung‐Sang Yu, In‐Jin Jang, SeungHwan Lee. Pharmacodynamics of tegoprazan and revaprazan after single and multiple oral doses in healthy subjects. Alimentary Pharmacology & Therapeutics 2020; 52(11-12): 1640 doi: 10.1111/apt.16121
|
| 32 |
Young-Min Han, Jong-Min Park, Song Her, Min Sun Kim, Yong Jin Park, Ki Baik Hahm. Revaprazan prevented indomethacin-induced intestinal damages by enhancing tight junction related mechanisms. Biochemical Pharmacology 2020; 182: 114290 doi: 10.1016/j.bcp.2020.114290
|
| 33 |
Ghazal Nabil, Yasmine H. Ahmed, Omaima Ahmed, Selvia S. Milad, Mohamed Hisham, Mohamed Rafat, Mohamed Atia, Aya A. Shokry. Argel's stemmoside C as a novel natural remedy for mice with alcohol-induced gastric ulcer based on its molecular mechanistic pathways. Journal of Ethnopharmacology 2024; 327: 117970 doi: 10.1016/j.jep.2024.117970
|
| 34 |
Ahmed Al-Marhabi, Ahmed Hashem, Bader Faiyaz Zuberi, Charles Onyekwere, Imran Lodhi, Mohamed Mounir, Saad Alkhowaiter, Sameer Al Awadhi, Vasudevan G. Naidoo, Yasser Hamada. The views of African and Middle Eastern Gastroenterologists on the management of mild-to-moderate, non-erosive gastro-esophageal reflux disease (GERD). Expert Review of Gastroenterology & Hepatology 2022; 16(3): 217 doi: 10.1080/17474124.2022.2043744
|